Expression of Growth Factors and Growth Factor Receptor in Non-healing and Healing Ischaemic Ulceration

European Journal of Vascular and Endovascular Surgery

Volumn 31, Issue 5, 2006, Pages 516-522

  Murphy, M O ^a,b   Ghosh, J ^a,b   Fulford, P ^a   Khwaja, N ^a   Halka, A T ^a,b   Carter, A ^a   Turner, N J ^a,b   Walker, M G ^a,b  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Angiogenesis; Healing; Ischaemic ulceration; Revascularisation

Indexed keywords

EOSIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; HEMATOXYLIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3; TRANSFORMING GROWTH FACTOR RECEPTOR BETA3; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BIOPSY; CAPILLARY; CELL COUNT; CELL KINETICS; CELL PROLIFERATION; CELL SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMIS; ENDOTHELIUM; EPITHELIUM CELL; FEMALE; GENETIC MANIPULATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFECTION; INFLAMMATION; ISCHEMIA; MACROPHAGE MIGRATION; MALE; MORPHOLOGY; NECROSIS; NEUTROPHIL CHEMOTAXIS; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVASCULARIZATION; SKIN FIBROBLAST; SMALL VESSEL VASCULITIS; ULCER; ULCER HEALING; VASCULITIS;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISCHEMIA; LEG; LEG ULCER; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; WOUND HEALING;

EID: 33645910202     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2005.12.002     Document Type: Article

References (30)

1. Miller M.E. Cutaneous infections and disorders of inflammation. J Am Acad Dermatol 2 1 (1980) 1-22
2. Baker S.R., Stacey M.C., Singh G., Hoskin S.E., and Thompson P.J. Aetiology of chronic leg ulcers. Eur J Vasc Surg 6 3 (1992) 245-251
3. Fowkes F.G. Epidemiological research on peripheral vascular disease. J Clin Epidemiol 54 9 (2001) 863-868
4. Sumpio B.E. Foot ulcers. N Engl J Med 343 11 (2000) 787-793
5. Taylor Jr. L.M., Edwards J.M., and Porter J.M. Present status of reversed vein bypass grafting: five-year results of a modern series. J Vasc Surg 11 2 (1990) 193-205 [discussion 205-206]
6. Berceli S.A., Chan A.K., Pomposelli Jr. F.B., Gibbons G.W., Campbell D.R., Akbari C.M., et al. Efficacy of dorsal pedal artery bypass in limb salvage for ischemic heel ulcers. J Vasc Surg 30 3 (1999) 499-508
7. Hafner J., Schaad I., Schneider E., Seifert B., Burg G., and Cassina P.C. Leg ulcers in peripheral arterial disease (arterial leg ulcers): impaired wound healing above the threshold of chronic critical limb ischemia. J Am Acad Dermatol 43 6 (2000) 1001-1008
8. Seeger J.M., Pretus H.A., Carlton L.C., Flynn T.C., Ozaki C.K., and Huber T.S. Potential predictors of outcome in patients with tissue loss who undergo infrainguinal vein bypass grafting. J Vasc Surg 30 3 (1999) 427-435
9. Raines E.W. PDGF and cardiovascular disease. Cytokine Growth Factor Rev 15 4 (2004) 237-254
10. Wells A. EGF receptor. Int J Biochem Cell Biol 31 6 (1999) 637-643
11. Ghosh J., Murphy M.O., Turner N., Khwaja N., Halka A., Kielty C.M., et al. The role of transforming growth factor beta(1) in the vascular system. Cardiovasc Pathol 14 1 (2005) 28-36
12. Lagattolla N.R., Stacey M.C., Burnand K.G., and Gaffney P.G. Growth factors, tissue and urokinase-type plasminogen activators in venous ulcers. Ann Cardiol Angeiol (Paris) 44 6 (1995) 299-303
13. Peschen M., Grenz H., Brand-Saberi B., Bunaes M., Simon J.C., Schopf E., et al. Increased expression of platelet-derived growth factor receptor alpha and beta and vascular endothelial growth factor in the skin of patients with chronic venous insufficiency. Arch Dermatol Res 290 6 (1998) 291-297
14. Peschen M., Grenz H., Grothe C., Schopf E., and Vanscheidt W. Patterns of epidermal growth factor receptor, basic fibroblast growth factor and transforming growth factor-beta3 expression in skin with chronic venous insufficiency. Eur J Dermatol 8 5 (1998) 334-338
15. Jude E.B., Blakytny R., Bulmer J., Boulton A.J., and Ferguson M.W. Transforming growth factor-beta 1, 2, 3 and receptor type I and II in diabetic foot ulcers. Diabet Med 19 6 (2002) 440-447
16. Ferguson M.W., Herrick S.E., Spencer M.J., Shaw J.E., Boulton A.J., and Sloan P. The histology of diabetic foot ulcers. Diabet Med 13 Suppl 1 (1996) S30-S33
17. Falanga V., Eaglstein W.H., Bucalo B., Katz M.H., Harris B., and Carson P. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers. J Dermatol Surg Oncol 18 7 (1992) 604-606
18. Bennett S.P., Griffiths G.D., Schor A.M., Leese G.P., and Schor S.L. Growth factors in the treatment of diabetic foot ulcers. Br J Surg 90 2 (2003) 133-146
19. Wahlberg E. Angiogenesis and arteriogenesis in limb ischemia. J Vasc Surg 38 1 (2003) 198-203
20. Betsholtz C., Lindblom P., and Gerhardt H. Role of pericytes in vascular morphogenesis. EXS 94 (2005) 115-125
21. Simons M., Annex B.H., Laham R.J., Kleiman N., Henry T., Dauerman H., et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 105 7 (2002) 788-793
22. Henry T.D., Annex B.H., McKendall G.R., Azrin M.A., Lopez J.J., Giordano F.J., et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 107 10 (2003) 1359-1365
23. Grines C.L., Watkins M.W., Helmer G., Penny W., Brinker J., Marmur J.D., et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105 11 (2002) 1291-1297
24. Hedman M., Hartikainen J., Syvanne M., Stjernvall J., Hedman A., Kivela A., et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 107 21 (2003) 2677-2683
25. Lederman R.J., Mendelsohn F.O., Anderson R.D., Saucedo J.F., Tenaglia A.N., Hermiller J.B., et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 359 9323 (2002) 2053-2058
26. Rajagopalan S., Mohler III E., Lederman R.J., Saucedo J., Mendelsohn F.O., Olin J., et al. Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: design of the RAVE trial. Am Heart J 145 6 (2003) 1114-1118
27. Palmer-Kazen U., Wariaro D., Luo F., and Wahlberg E. Vascular endothelial cell growth factor and fibroblast growth factor 2 expression in patients with critical limb ischemia. J Vasc Surg 39 3 (2004) 621-628
28. Choksy S., Pockley A.G., Wajeh Y.E., and Chan P. VEGF and VEGF receptor expression in human chronic critical limb ischaemia. Eur J Vasc Endovasc Surg 28 6 (2004) 660-669
29. Shah M., Revis D., Herrick S., Baillie R., Thorgeirson S., Ferguson M., et al. Role of elevated plasma transforming growth factor-beta1 levels in wound healing. Am J Pathol 154 4 (1999) 1115-1124
30. Wehrhan F., Grabenbauer G.G., Rodel F., Amann K., and Schultze-Mosgau S. Exogenous modulation of TGF-beta(1) influences TGF-betaR-III-associated vascularization during wound healing in irradiated tissue. Strahlenther Onkol 180 8 (2004) 526-533